1Garcia PA,Aminoff MJ, Goodin DS,et al.The frontal N30 of the median- derived SEP in patients with predominantly unilateral Parkinson s disease.Neuorology,1995,45(5):989-992.
3Leuchter AF,Cook IA,Newton TF,et al.Regional differences in brain electricalactivity in dementia:use of spectral power and spectral ratio measure.Electroenceph ClinNeurophysiol,1993,87:385
2Errea AJM, Ara CJR, Aibar RC. Drug-induced parkinsonism, Clinical aspects compared with parkinson's disease. Rev Neurol,1998, 27 (155): 35-39.
3Masmoucli K, Gras CV,Masson H, et al. Parkinsonism and/ or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry,2006, 39 (1) : 9-12.
4Marti MJF, Poza JJ. Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs. Neurologia, 1996,11(1) :1015.
5Bower JH, Maraganore DM, Mcdonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County. Minnesota,1976-1990. Neurology,1999,52(6):1214-1220.
6Llau ME, Nguyen L, Senard JM, et al. Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance. Rev Neurol, 1994,150 ( 11 ): 757-762.
7Marti MJF, Poza JJ. Cinnarizine- induced parkinsonism: ten years later. Mov Disord, 1998,13 (3) : 458-456.
8Masmoudi K, Gras CV, Masson H, et al. Parkinsonism and/ or cognitive impairmentwith valproic acid therapy: a report of ten cases. Pharmacopsychiatry, 2006,39 ( 1 ) : 9-12.
9Noyes K, Liu H, Holloway RG. What is the risk of developing parkinsonism following neuroleptic use. Neurology,2006, 66(6) :941-943.
10Rochon PA, Stukel TA, Sykora R,et al, Atypical antipsychotcs and parkinsonism. Arch Intern Med, 2005,165 (16) :1882- 1888.
